{
    "organizations": [],
    "uuid": "9faf26dafa9b00f66d5d63d4c3a5d7c812fdb436",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/12/globe-newswire-athersys-to-host-year-end-2017-financial-results-call.html",
    "ord_in_thread": 0,
    "title": "Athersys to Host Year-End 2017 Financial Results Call",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) will release its year-end 2017 financial results at approximately 4:00 PM Eastern Time on Tuesday, March 13, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:\nDate March 13, 2018 Time 4:30 p.m. (Eastern Time) Telephone access: US and Canada (800) 273-1254 Telephone access: International (973) 638-3440 Access code 8898346 Live webcast www.athersys.com under Investors section A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on March 27, 2018 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 8898346.\nAbout Athersys\nAthersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem Â® cell therapy product, a patented, adult-derived \"off-the-shelf\" stem cell product, initially for disease indications in the neurological, cardiovascular, and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com .\nATHX-G\nContact:\nWilliam (B.J.) Lehmann, J.D.\nPresident and Chief Operating Officer\nTel: (216) 431-9900\nbjlehmann@athersys.com\nKaren Hunady\nCorporate Communications and Investor Relations\nTel: (216) 431-9900\nkhunady@athersys.com\nDavid Schull\nRusso Partners, LLC\nTel: (212) 845-4271 or (858) 717-2310\nDavid.schull@russopartnersllc.com\nSource:Athersys, Inc.",
    "published": "2018-02-12T21:30:00.000+02:00",
    "crawled": "2018-02-12T23:33:10.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cleveland",
        "globe",
        "newswire",
        "athersys",
        "nasdaq",
        "athx",
        "release",
        "financial",
        "result",
        "approximately",
        "pm",
        "eastern",
        "time",
        "tuesday",
        "march",
        "host",
        "conference",
        "call",
        "shortly",
        "thereafter",
        "pm",
        "eastern",
        "time",
        "review",
        "result",
        "gil",
        "van",
        "bokkelen",
        "chairman",
        "chief",
        "executive",
        "officer",
        "william",
        "lehmann",
        "president",
        "chief",
        "operating",
        "officer",
        "host",
        "call",
        "follows",
        "date",
        "march",
        "time",
        "eastern",
        "time",
        "telephone",
        "access",
        "u",
        "canada",
        "telephone",
        "access",
        "international",
        "access",
        "code",
        "live",
        "webcast",
        "investor",
        "section",
        "replay",
        "available",
        "listening",
        "shortly",
        "completion",
        "call",
        "pm",
        "eastern",
        "time",
        "march",
        "aforementioned",
        "url",
        "dialing",
        "canada",
        "abroad",
        "entering",
        "access",
        "code",
        "athersys",
        "athersys",
        "international",
        "biotechnology",
        "company",
        "engaged",
        "discovery",
        "development",
        "therapeutic",
        "product",
        "candidate",
        "designed",
        "extend",
        "enhance",
        "quality",
        "human",
        "life",
        "company",
        "developing",
        "multistem",
        "cell",
        "therapy",
        "product",
        "patented",
        "stem",
        "cell",
        "product",
        "initially",
        "disease",
        "indication",
        "neurological",
        "cardiovascular",
        "inflammatory",
        "immune",
        "disease",
        "area",
        "several",
        "ongoing",
        "clinical",
        "trial",
        "evaluating",
        "potential",
        "regenerative",
        "medicine",
        "product",
        "athersys",
        "forged",
        "strategic",
        "partnership",
        "broad",
        "network",
        "collaboration",
        "advance",
        "multistem",
        "cell",
        "therapy",
        "toward",
        "commercialization",
        "information",
        "available",
        "contact",
        "william",
        "lehmann",
        "president",
        "chief",
        "operating",
        "officer",
        "tel",
        "bjlehmann",
        "karen",
        "hunady",
        "corporate",
        "communication",
        "investor",
        "relation",
        "tel",
        "khunady",
        "david",
        "schull",
        "russo",
        "partner",
        "llc",
        "tel",
        "source",
        "athersys",
        "inc"
    ]
}